Volume 20, Number 1—January 2014
Research
Multisite Validation of Cryptococcal Antigen Lateral Flow Assay and Quantification by Laser Thermal Contrast
Table 1
Characteristic |
2006–2009, Retrospective |
2010–2012, Prospective* |
||
---|---|---|---|---|
Demographic |
Kampala, Uganda |
Kampala, Uganda |
Mbarara, Uganda |
Cape Town, South Africa |
Location | ||||
No. persons | 299 | 354 | 142 | 37 |
Mean ± SD age, y | 36 ± 8 | 35 ± 9 | 35 ± 11 | 37 ± 10 |
Male sex, no. (%) | 168 (56) | 174 (49) | 87 (61) | 22 (59) |
CD4 cell count/μL median (IQR) | 19 (7–38) | 16 (7–69) | 36 (14–74) | 65 (43–97) |
Diagnostic tests performed, no. | ||||
CSF | ||||
Quantitative culture | 282 | 345 | 142 | 37 |
Latex agglutination | 279 | 345 | 142 | 37 |
India ink microscopy | 276 | 350 | 142 | 37 |
LFA | 197 | 291 | 142 | 36 |
Serum | ||||
Latex agglutination | 85 | 34 | NA | NA |
LFA | NA | 274 | 49 | 23 |
Plasma | ||||
LFA | 60 | NA | NA | NA |
Urine | ||||
LFA | NA | 185 | 51 | NA |
*IQR, interquartile range; CSF, cerebrospinal fluid; LFA, lateral flow immunochromatographic assay; NA, not available.
†Prospective testing with LFA because point-of-care began in April 2011. Eighty LFAs were conducted on cryopreserved samples.
Page created: January 03, 2014
Page updated: January 03, 2014
Page reviewed: January 03, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.